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Cancer is a growing problem. In the US, cancer is roughly tied with cardiac 
disease as the leading cause of death. Intriguingly, compared to the proportion of 
deaths attributable to primary tumors, roughly 90% of all cancer patient morbidity and 
mortality are a direct result of metastatic disease perturbing normal organ and system 
function. Research has shown that the propensity to form both spontaneous tumors and 
metastatic growths is a function of both the nuclear and mitochondrial genomes present 
within an organism. Specifically, studies have also shown that, when the nuclear 
background is held constant and the mitochondrial haplotype is varied, there are 
marked discrepancies in both tumor latency and the average number of metastatic 
growths observed. To further study the effects of varying the mitochondrial haplotype on 
cancer progression and metastasis, a unique in vivo model—known as Mitochondrial-
Nuclear Exchange (MNX) mice—has been developed.  Experiments using this model 
system further support the notion that mitochondrial haplotype can contribute 
significantly to tumor latency and the overall of metastatic growths. As an initial line of 
inquiry, the question was asked as to whether or not differences in gene expression 
could be present upon changing the mitochondrial haplotype. Given that clear 
differences in genome-wide expression profiles between wildtype and MNX mice were 
indeed observed, the next line of inquiry sought to determine whether or not DNA 
methylation profiles could be regulating the differences in expression. Likewise, 
significant differences in DNA methylation patterns were established. As a corollary to 
these findings, the subsequent line of inquiry sought to elucidate whether or not 
mitochondrial haplotype could influence other potential epigenetic mechanisms 
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responsible for the differences in gene expression profiles. Specifically, given the known 
link between metabolism and epigenetics, the logical hypothesis of the experiment was 
simply that the mitochondrial haplotype could potentially able to directly influence the 
epigenetic process of post-translationally modifying the N-terminal tails of histones in 
order to affect chromatin state dynamics in the cell. To address this hypothesis, 
following rigorous antibody validation, a ChIP-Seq experiment comparing wildtype and 
MNX mice using antibodies against four known histone modifications (H3K4me1, 
H3K4me3, H3K27me3, and H3K27ac) was conducted. Post-sequencing analysis 
indicated a selective difference in the overall profile of differentially-bound, post-
translationally modified histones, thus supporting the hypothesis that mitochondrial 
haplotype does directly contribute to overall histone modification profiles. As a next 
logical step, future work will involve integrating previously generated RNA-Seq, Methyl-
Seq, and ChIP-Seq experiments (in combination with extensive metabolome data) to 
develop hypotheses as to possible causal mechanisms involved in driving the observed 
differences in tumor latency and metastatic growth. Furthermore, another direction 
could involve expanding the ChIP-Seq study to include newly characterized acylation 
(propionylation, butyrylation, succinylation, malonylation, etc.) post-translational 
modifications which functionally are thought to overlap with acetylation and may more 
closely link metabolism to overall chromatin state. The results of this research not only 
contribute to our understanding of how mitochondria participate in influencing the DNA 
packaging mechanisms involved in regulating chromatin dynamics, but, as our research 
is not limited to any single form of cancer, has the potential to benefit to all cancer 
patients.   
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On the microscopic, molecular level, cancer evolution is a beautifully Darwinian 
process [1]. Cells that sustain growth and survival advantages are able to generate 
more progeny with the same characteristics (e.g., deregulated cell cycle control or 
resistance to cell death and senescence mechanisms. The result is ultimately a clonal 
expansion with either a few or—often—many heterogeneous sub-clonal populations 
comprising a tumor and simultaneously co-evolving [2].  On the macroscopic level, the 
uncontrolled expansion of cancer cells can overtake and replace normal, healthy cells 
and tissues with non-functioning, cancerous equivalents.  The ensuing tissue damage 
can eventually instigate organ malfunction and endanger the patient if left untreated. If 
the cancer spreads to other distant organs or anatomical locations, the implications for 
the outcome of the patient are usually severe [3].   
In the US alone, cancer is roughly tied with cardiac disease as the leading cause 
of death [4]. About 40% (or 2 in 5 individuals) of the total population will develop some 
form of cancer of the course of their lives [5].  While death rates due to cancer have 
been consistently decreasing over the past few decades for most forms of cancer, the 
lifetime risk of dying to cancer presently stands at 20%, (or 1 in 5 individuals) [5]. 
Intriguingly, relatively few cancer patients succumb to their primary tumors. Many 
neoplasms, if detected early in their benign and in situ forms, are usually able to be 
readily excised or otherwise treated to produce an essentially disease-free state. As 
such, only around one in ten patient deaths are directly attributable to primary 
neoplasia-induced complications. Unfortunately, many types of cancer are 
asymptomatic or have vague symptoms and are not detected until the cancer has 
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matured to a more advanced, malignant state capable of invading other tissues and 
metastasizing to distant sites within the body. Metastatic disease is extremely difficult to 
treat and cure. Due to increasing genomic instability and selective pressures exerted by 
prophylaxis (such as chemotherapeutic regimens), cell populations within secondary 
tumors are able to evolve rapidly and are likely exhibit resistance to treatments (due to 
surviving exposure to initial chemotherapeutics or possibly due to sustaining new 
mutations effectively conferring drug resistance). Compared to the proportion of deaths 
attributable to primary tumors, roughly 90% of all cancer patient deaths are directly a 
result of metastatic disease perturbing normal organ and system function [6]. Not all 
primary tumors have the same likelihood to metastasize, however [7]. 
Indeed, some forms of primary cancer rarely metastasize. Basal cell carcinomas, 
for example, generally do not spread beyond the patient’s skin [8] and gliomas usually 
remain contained within the brain and CNS (although aberrant neoplasia in the brain—
even without distant spreading—overgrows regular, healthy neighboring tissue, 
interferes with normal function, and can still threaten the patient’s life) [9].  On the other 
hand, while most cancers can metastasize, certain types of cancer are known to 
metastasize at very high rates (such as melanomas) [7]. The tissue of origin of the 
primary tumor can also have a significant impact on the location(s) where metastatic 
disease may likely form in a patient [10]. Some high-grade primary cancers (such as 
breast cancer, lung cancer, and melanomas) are able to establish distant colonies in a 
very promiscuous manner (i.e., disease can spread to many host tissues and organs).  
Other certain types of advanced primary neoplasia appear to exhibit “metastatic 
tropism”, whereby metastatic colonies form in organs and locations in a somewhat 
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predictable manner [11]. For example, metastatic disease originating from prostate 
cancer often colonizes bones, primary colorectal cancer tends to selectively form 
secondary growths in the liver, and in the event primary lymphoma in the lymph system 
and blood manages to form metastatic growths in the bones, liver, or brain [11]. The 
precise mechanisms and events required for cells to be able to undergo the process of 
metastasis are still not well understood. For instance: why do macroscopic primary 
tumors, which can shed millions of transformed cells into the blood stream each day 
[12], often form only relatively few metastatic growths [13] ? 
To address such a question, several general processes involved in enabling a 
benign neoplastic growth to transform into distant, malignant disease have been 
described. As over 80% of malignant cancer involves carcinomas of epithelial origin 
[14], the processes describing the complex invasion-metastasis cascade will largely be 
in reference to this class of tumors. 
In brief, resident cancer cells comprising an in situ primary tumor must locally 
invade by degrading and ultimately penetrating the basal lamina, a specialized 
proteinaceous extracellular matrix physically separating the epithelium from the stroma 
[15]. Upon invading the stroma itself, cancer cells may have the opportunity to enter 
blood or lymph system vasculature via the process of intravasation (possibly through 
interactions with macrophages in order to pass by endothelial cells of vessel walls) [15]. 
Once in circulation, cancer cells must overcome significant challenges, including 
evading anchorage-dependent programmed cell death (anoikis), being able to grow and 
proliferate without supportive signals from stromal constituents, and simply not being 
killed by the immune system or torn to shreds by hydrodynamic forces experienced 
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while circulating [15]. To increase their odds of survival, circulating cancer cells can 
associate with a sheath of blood platelets [16]. Although, despite the presence of CTCs 
in the blood, very few of these blood-borne pioneers manage to successfully establish 
secondary growths at distant sites. One significant method (apart from interactions with 
cell surface adherence receptors) through which cells can begin to extravasate (exit) the 
bloodstream is through being trapped within capillaries of organs [15]. For example, 
many capillaries range between 3 to 8µm wide, whereas circulating cancer cells in the 
blood are often 20µm or more [17]. Once trapped in the vessel, the circulating cancer 
cell must penetrate through the endothelial wall. Similar to how the cancer cells initially 
intravasated, cancer cells can extravasate through association with a macrophages or 
they can even begin to proliferate within the lumen of the vessel itself in order simply 
break through the endothelial wall [15]. The final step of the metastatic cascade is the 
successful colonization of distant tissues and organs [15]. Even though cancer cells 
may survive the journey to the foreign site, the new local environment will be very 
different from the environment of origin [18].  Many of the supporting and growth factors 
present within the primary tumor will likely be absent at the new location. As such, most 
micrometastatic growth are able to maintain only a state of stasis and never grow to 
become readily-observable neoplasms [19]. Thankfully, the overall rate of metastatic 
efficiency is very low and few micrometastases are able to exit their essentially 
proliferatively-senescent states in order to form macrometastases [15].   
As one might imagine, there are certain genes which can act to promote specific 
steps of the metastatic cascade. For instance, downregulation of E-Cadherin 
contributes to a shift from an epithelial (strong Upregulation of ECM-modifying proteins 
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(such as MMPs, collagenases, and other proteases) can actively promote degradation 
of the basal lamina and autocrine expression of TFG-β enables cancer cells to 
proliferate in a stroma-independent manner. Given that there are a set of genes that can 
promote metastasis, there have likewise been a set of genes discovered that have been 
shown to actively suppress metastatic spread [20]. In a manner similar to that of tumor 
suppressor genes, metastasis suppressor genes act to prevent the occurrence of 
metastatic disease, albeit without having any significant effect on the growth of the 
primary tumor itself. Many such genes were discovered by observing which genes were 
upregulated/actively expressed in primary tumors and downregulated/repressed in 
secondary growth. Some metastasis suppressor genes have clear ties to specific steps 
in the metastatic cascade, whereas the mechanisms of other metastasis suppressor 
genes are decidedly less clear [21].  Several putative metastasis suppressor genes 
such as KISS1, BRMS1, and ITIH5 (among several others) are being evaluated through 
careful investigation [22-25]. 
A keystone paper from Kent Hunter in 2006 revealed that the host genetic 
contribution to metastatic cancer formation may be significantly more complex than first 
meets the eye [26]. In his paper, Hunter showed that the genetic background of the host 
can dramatically affect the capacity to form metastatic disease.  In the experiment, 
Hunter bred male FVB/NJ-TgN(MMTV-PyMT)634Mul mice (transgenic mice expressing 
the polyoma middle-T antigen), which present with spontaneous tumors within 60 days 
and roughly 90% of the mice form secondary growth in their lungs within 100 days, with 
female mice of several different inbred stains. The result was that mice formed 
pulmonary metastases to significantly varying degrees. The straight-forward explanation 
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for this observation would be that the differences were simply due to the nature of the 
nuclear genome (strain-specific mutations; epigenetic dissimilarities) and this 
hypothesis was partly proven due to the discovery of distinct metastasis suppressor 
genes. What Hunter did not evaluate was the possibility that the observed differences 
could have been due to differences in the maternally-inherited mitochondrial haplotypes 
of the mice (although, in his 2018 paper, Hunter does recognize recent findings in the 
Welch lab which show the contribution of mitochondria and metabolism to the formation 
of metastatic disease) [27]. 
Mitochondria are widely known as the “powerhouses” of the cell, as they 
generate most of the intracellular ATP (in addition to having roles in cell death). 
Embedded within the inner membrane of the mitochondrion are members of the 
electron transport chain family, which accept electrons from donor molecules (such as 
succinate, NADH, and FADH2) and ultimately reduce oxygen to water. Critical in the 
process is that the energy released through the incremental passage of electrons is 
used to produce a proton gradient in the intermembrane space (essentially pumping 
protons again their concentration gradient). ATP Synthase (another protein in the inner 
mitochondrial membrane) takes advantage of the proton gradient and energetically 
favorable tendency to move from high to low proton concentrations in order to catalyze 
the synthesis of ATP, one of the most important chemical energy sources in the cell. In 
order to generate the electron donors necessary for electron transport and efficient 
aerobic respiration, however, the citric acid cycle (also known as the tricarboxylic acid 
cycle or the Krebs cycle) is critical. The TCA cycle occurs within the mitochondrial 
matrix (innermost compartment) and oxidizes acetyl-CoA through a chain of reactions to 
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form electron donors (such as NADH and FADH2) and metabolite precursors for amino 
acids and other biomolecules. Acetyl-CoA can be generated primary through 
breakdown of carbohydrates (via glycolysis), lipids (via β-oxidation), and ketone bodies. 
In the event there is insufficient oxygen available to receive electrons from the electron 
transport chain, anaerobic respiration increasingly attempts to use pyruvate as an 
electron acceptor in lieu of oxygen (to regenerate NAD+ from NADH) and produces 
lactic acid, ethanol, or other acids/alcohols. Fermentation is, however, a very inefficient 
process for producing NAD+ and ATP. Aerobic metabolism in the mitochondrion is 
roughly 15 times more efficient than fermentation in terms of overall ATP generation. As 
is evident, mitochondria are referred to as “powerhouses” for good reason.     
The presence of mitochondria likely arose in the eukaryote cell roughly 1.5 billion 
years ago through an endosymbiotic relationship in which a prokaryote was engulfed by 
a eukaryotic cell and managed to survive inside the eukaryote’s cytoplasm [28]. Since 
then, mitochondria have closely coevolved with eukaryotes, wherein many 
mitochondrial genes responsible for the electron transport complex have migrated to the 
nuclear genome [29]. However, critical components of the electron transport chain have 
remained under the control of the mitochondrion (within the mitochondrial genome) and 
mitochondria replicate through binary fission (a method very similar to prokaryotic 
division) [30]. Instead of dividing in sync with the cell cycle, mitochondria divide as per 
the situational metabolic demands of the cell.  As one might imagine, the metabolic 
demand of a cell depends on the function of the specific tissue in which the cell finds 
itself. For example, heart, muscles, brain, kidneys, and liver cells have high 
metabolic/energy demand and, accordingly, high cell proportions of mitochondria [31]. 
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The number of distinct mitochondria (although complex to count due to the nature of 
fused and non-fused mitochondria [32]) can range anywhere from the tens to several 
thousand [33].  
The mitochondrial genome, by itself, is rather small and unassuming [34]. In 
human mitochondria, a circular dsDNA molecule comprises the mitochondrial DNA 
(mtDNA) and is roughly 16,000bp in length. The mtDNA codes for 37 unique genes, 
specifically 13 respiratory complex subunit genes (I,III, IV, V), 22 mitochondrial tRNA, 
and two rRNA. The haploid human genome, as a comparison, is over 3 billion bp in 
length. Given that each individual mitochondrion contains between two and ten copies 
of its genome and that there are many mitochondria per cell, the “effective” size of the 
entire collection of mtDNA can surprising (sometimes approaching 4% of the genetic 
material in the cell) [35].  However, unlike the nuclear genome, mitochondria (and hence 
the mtDNA) are entirely inherited from the oocyte of the mother [36, 37], while the 
paternal mitochondria present in the sperm are hypothesized to be degraded via 
ubiquitination after fertilization [38]. This process allows maternal ancestry to be 
inferred, somewhat analogous to how the Y chromosome can be used to trace the 
paternal lineage.  
As one might imagine, several human diseases result from damaged or 
dysfunctional mitochondria. Of the diseases that do arise, roughly 15% are a result of 
mutations in the mtDNA itself (whereas the other 85% of mitochondrial diseases stem 
from mutations to metabolic genes in the nuclear genome) [39].  Symptoms of 
malfunctioning mitochondria essentially run a very wide gamut. Everything from muscle, 
vision, auditory, nerve, and internal organ function (such as the liver/kidneys/heart) can 
9 
 
all be perturbed.  Specific examples of mitochondrial diseases include Leigh disease 
(neurologic and system-wide failure due to metabolic stress) [40], Pyruvate 
Dehydrogenase Complex Deficiency (lethargy, respiratory failure, coma, ataxia, 
neuropathy) [41], and Pearson Syndrome (anemia/neutropenia/thrombocytopenia due 
to affected hematopoietic stem cells, insufficient pancreatic function, general systemic 
failure) [42]. Clearly, having enough available energy and functioning metabolic 
pathways is imperative to good health. If parts of mitochondria-mediated metabolism 
are not working normally, sever systemic disease can result.  
Cancer cells exhibit their own unique form of energy metabolism. As reported by 
the famous Otto Warburg in 1924, even when cancer cells have access to sufficient 
oxygen, often the cells do not readily undergo oxidative phosphorylation—instead 
preferring to generate lactic acid via strongly upregulated glycolysis (often despite 
having normally functioning respiration components) [43]. Energetically, the process of 
aerobic glycolysis is a poor trade off in efficiency when comparing ATP generated by 
the two processes (2 ATP vs 30-36 ATP). In order to feed their hunger for glycolysis, 
cancer cells import very high quantities of glucose, which is often made possible 
through upregulated glucose transporters in the cell plasma membrane.  A possible 
explanation for such a dramatic shift in metabolism could be that the intermediate 
metabolites generated through glycolysis could be used to fuel anabolic reactions and 
drive proliferation. Another possible explanation stems from possible competition 
between tumor cells and T immune cells. As a result of tumor cells 
consuming/outcompeting T cells for glucose, T cells are effectively weakened and 
exhibit decreased mTOR signaling, IFN production, and inhibits the production of anti-
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tumor cytokines involved in tumor clearance [44].  That being said, Warburg’s 
observations were fairly large generalizations. Not all cancer types exhibit Warburg 
metabolism (due to possible metabolic heterogeneity) [45] and research suggests that 
cancer cells retain their ability to both Warburg metabolism and oxidative 
phosphorylation in order to increase adaptability [46]. Unfortunately, the role of 
mitochondria in the contribution to cancer is complex and often complicated by 
environmental dynamics, tissue-specific factors, and genetics.  
One well-studied method through which mitochondrial energy metabolism can 
influence cancer is the generation of reactive oxygen species (ROS) [47]. During the 
process of oxidative phosphorylation, oxygen receives electrons in a controlled manner 
in order to be reduced to H2O. The OxPhos system, however, is by no means perfect 
and normally exhibits a low rate of leak, wherein a small percentage (< 2%) of electrons 
incompletely reduce oxygen and form •O2-, superoxide, a radical which can deleteriously 
react with other biomolecules in the cell. Fortunately, cells have enzymes which act as 
an antioxidant defense system and catalyze the conversion of ROS radicals to less 
reactive molecules. For example, the enzyme Superoxide Dismutase can convert 
superoxide into hydrogen peroxide and oxygen. Hydrogen peroxide itself is also a 
member of the ROS family and the Catalase enzyme (among a few others) can actively 
convert hydrogen peroxide into water and oxygen. Outside of normal homeostasis, high 
levels of ROS and the associated oxidative stress can be detrimental to the integrity of 
the cell and ultimately result in cell death [48]. Low levels of ROS, on the other hand, 
can be involved in potentiating proliferation and survival [48]. Cancer cells often exhibit 
elevated ROS levels and are reliant on NAPDH-dependent antioxidant activity via 
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reduced glutathione and thioredoxin. Interestingly, many chemo- and radiotherapeutic 
regimens actually function by further increasing intracellular ROS levels (rather than by 
decreasing ROS) [49]. Normal cells have lower basal ROS levels and can survive 
increased oxidative stress, whereas cancer cells often cannot [48, 50, 51].  
In the context of metastasis, the role is ROS is less clear and is dependent on 
the stage of disease development [52]. At low levels, mitochondrial ROS act as an 
intracellular, retrograde signaling mechanism to promote cancer survival and 
proliferation through activation of ROS-dependent growth factors [53]. ROS have also 
been linked to chronic inflammation by contributing to the microenvironment necessary 
to support neoplasia. On the other hand, high levels of ROS can contribute to initiation 
of cancer and disease progression [53]. For example, interactions of misregulated ROS 
with biomolecules (such as DNA) can result in DNA lesions and double-strand breaks, 
thus potentially contributing to inactivation of tumor suppressors or oncogene activation. 
ROS also play key roles at each step of the metastatic cascade, which has been 
described in the literature [54]. 
As one might imagine, mitochondrial haplotype (and thus overall energy 
metabolism) can significantly affect the epigenetic profile within a cell [55, 56]. The term 
“epigenetics” is defined as any heritable method for regulation of gene expression apart 
from manipulation of the DNA sequence itself (“epi” = above, on, over) and epigenetics 
is the reason for why, although essentially all cells in the body have the same genetic 
complement, there exists a wide variety of cell types, each with unique expression 
programs, phenotypes, and physiological roles. The field of epigenetics is fairly young. 
While Jean-Baptiste Lamarck (~1800 A.D.) and Charles Darwin (1868) both 
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hypothesized that environmental factors could influence heritable traits, though 
evidence for the presence of epigenetic machineries did not start to significantly 
accumulate until the twentieth century [57-62]. Examples of epigenetic mechanisms 
include DNA methylation, microRNAs, and post-translational modification of chromatin 
packaging proteins (i.e., histones) [63-66].  
The direct, covalent modification of DNA via the addition of methyl groups plays a 
very important role in regulation of gene expression within a cell [67]. Of the four 
canonical DNA bases—adenine, thymine, cytosine, and guanine—two can be 
methylated: adenine and cytosine (of which only cytosine has been well studied) [68]. 
The addition of a methyl group to DNA (primarily to the C5 locus on cytosine’s 
pyrimidine ring) is catalyzed via DNMT family enzymes in mammals at the many (~29 
million) CpG dinucleotide motifs [69]. De novo DNA methyltransferases are involved in 
early establishment of the genomic DNA methylation pattern, whereas maintenance 
DNA methyltransferase enzymes are primarily responsible for re-establishing DNA 
methylation following DNA replication via recognition of hemi-methylated sites [70]. 
Reversal of DNA methylation occurs via the TET (ten eleven translocation) family of 
enzymes [71]. While methylated CpG moieties do not individually block transcription, 
DNA methylation is known for suppressing transcription activity when methylation is 
sufficiently dense (islands) within a genetic locus [72].  For example, high levels of 
methylation localized within promoter regions have been shown to inhibit gene 
transcription, DNA methylation also plays a critical role in suppressing the mobility of 
transposon elements, and normal embryonic development likewise relies on methylation 
in order to inactivate/silence genes involved in certain stages of embryogenesis and to 
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imprint maternal and paternal genomes with sex-specific methylation profiles [72-74]. 
Alternatively, methylation of the gene body (i.e., not within the promoter region) has 
actually been shown to be strongly associated with highly transcribed genes, possibly 
due to either inhibiting secondary promoters or to potentiating the rate of elongation or 
transcript splicing [75].   
Perhaps unsurprisingly, aberrant DNA methylation is often an important factor in 
cancer initiation and progression [64].  Cancer is frequently described as a disease of 
the genome, characterized by a high degree of genetic heterogeneity. Given that the 
DNA methylation program can be drastically altered through sustained mutations to 
metabolic pathways such as the TCA cycle and epigenome modifying enzymes, 
epigenetic heterogeneity may also be playing a key role in the evolution of tumors [76-
79]. Tumor initiation can be promoted via hypermethylation of tumor suppressors (such 
as DNA repair genes) and oncogenic hypomethylation of the genome [80, 81]. In the 
context of tumor progression and metastasis, the specific genes affected by changes in 
DNA methylation vary depending on cell type and primary and secondary site 
microenvironments [82]. For instance, hypermethylation of tumor suppressors often 
occurs very early in cancer and hypermethylation of metastasis suppressor genes 
would likely only provide a growth/survival advantage at late stages of cancer 
progression [83]. Global, heterogeneous hypomethylation would allow for disease 
progression via phenotypic plasticity, allowing for a population of cancer cells to evolve 
and adapt to the differing stresses and demands of the metastatic cascade [84, 85].  
A second significant epigenetic mechanism through which cells can regulate 
gene expression takes the form of non-coding RNAs. This group of RNAs includes long 
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non-coding RNA (lncRNA) and small non-coding RNA, such as siRNA (small 
interfering), snRNA (small nuclear), snoRNA (small nucleolar), and miRNA (microRNA), 
among several others. While many non-coding RNA transcripts appear to be the result 
of non-selective, cryptic transcription (essentially intergenic RNA), other non-coding 
RNAs have been shown to have biological functions [86]. One fairly well-characterized 
class of non-coding RNA are microRNAs, which range between 20 and 25 nucleotides 
long after maturation and function by binding to mRNA transcripts and modulating 
subsequent translation (either via inhibition of translation or promoting degradative 
cleavage of the transcript itself) [87]. As such, miRNAs represent an important method 
of epigenetic regulation of protein translation. In the context of cancer, just like regular 
peptide-encoding genes, genetic loci encoding miRNA transcripts are subject to 
mutations and epigenetic regulation via methylation and chromatin dynamics [88]. Much 
as regular genes, miRNAs can also act in either an oncogenic or tumor suppressive 
manner (and the miRNAs are known as oncomiRs and tumor suppressor miRNAs, 
respectively) [89]. OncomiRs typically suppress tumor suppressor peptide translation 
(e.g., miR-21 modulates PTEN) and tumor suppressor miRNA downregulate 
oncoproteins (let-7 miRNA regulates RAS and Myc oncoproteins; let-7 expression can 
be throttled in cancer). Perturbation of normal miRNA expression can also contribute to 
all steps of the metastatic cascade. Such miRNAs involved in regulating the various 
steps of the metastatic cascade are known as metastamirs, which can have either pro- 
or anti-metastatic properties [90].   
Histones and their post-translational modifications comprise yet another 
important form of epigenetic regulation in the cell. Chromatin structure and the 
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accessibility of genetic loci are critical to determining the level of transcriptional 
permissiveness [91]. As one can imagine, the dynamic conformation of chromatin can 
drastically affect the ability of transcriptional machinery and transcription factors to bind 
to target loci and potentiate expression. The presence and/or combination of certain 
histone post translational modifications are associated with specific gene regions (such 
as binding to promoters or enhancers) and with transcriptional (such as active or 
repressed transcription) and chromatin states [92]. Heterochromatin is associated with 
strongly repressed gene expression and is visible as dense, dark-staining regions in the 
nucleus. Conversely, euchromatin is associated with activate transcription and is open 
and does not readily stain [93, 94]. In tumorigenesis, chromatin remodeling and histone 
modifying proteins can become mutated and misregulated, ultimately resulting in both 
aberrant epigenetic and expression programs [95].  
In order to play their critical role in the dynamic packaging of the genome, histone 
proteins are organized into octamers of histone subunits. Eukaryotic cells produce five 
canonical histone subunits, H1, H2A, H2B, H3, and H4, where H2A binds H2B and H3 
binds H4 as heterodimers and H1 is considered to be a linker protein (contributing to 
high-order chromatin status) [96]. Each of the canonical histone subunit’s expression 
levels are closely tied with S phase of the cell cycle and the coding sequences are 
extremely conserved throughout eukaryotes, as any perturbation in DNA packaging and 
chromatin conformation is likely to be highly detrimental to an organism [97, 98]. Two of 
each heterodimer (H2A-H2B, H3-H4) bind in order to form a functional DNA-binding unit 
and complete a nucleosome is formed when a histone octamer is wrapped 1.67 times 
by a 147bp strand of DNA [96].  
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Apart from the canonical histones, there exist many other histone subvariants 
which can be deposited into nucleosomes and which are associated with different 
chromatin conformations or specific chromosomal loci [99]. For example, histone H3 
has at least two known subvariants, including H3.3 and cenH3. H3.3 deposition takes 
place specifically at highly-transcribed genes, whereas cenH3 localized to centromeres 
and are involved in kinetochore assembly. The other well-studied histone is histone 
H2A, which has at least four additional subvariants (H2A.Z, H2A.X, H2A.B, macroH2A) 
[100].  Histone H2A.Z is unique in that the protein has evolutionarily diverged and is 
roughly 60% conserved compared to canonical H2A. H2A.Z has been associated with 
chromatin remodeling and, in eukaryotes, tends to correlate with actively expressed 
genes. The role of H2A.X is somewhat less clear-cut [101]. H2A.Xnull mice are infertile, 
as their spermatocytes are unable to properly condense and likewise cannot inactivate 
X and Y chromosome genes during meiotic division. In the context of DNA repair, upon 
induction of DNA damage (specifically, double-strand breaks), phosphorylation of 
H2A.X immediately occurs within the region of the strand break.  The initial 
phosphorylation event propagates throughout a large portion of the break region and 
persists until the lesion is repairs. Intriguingly, knockout of H2A.X does not abolish 
lesion repair, although the mutants do exhibit a reduction in repair efficiency and 
potentiated sensitivity to genotoxic insults. Lastly, H2A.B and macroH2A appear to play 
mutually exclusive roles in the process of X chromosome inactivation and dosage 
compensation. MacroH2A is strongly associated with inactive heterochromatin and can 
be readily found in inactivated X chromosomes (Barr bodies) [102, 103]. H2A.B, on the 
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other hand, is essentially undetectable in Barr bodies, but is widely distributed 
throughout the genome at actively expressed genetic loci [104, 105].  
Several diverse mechanisms are responsible for either writing, erasing, or 
reading post-translationally modified histone tails and thus leading to appropriate shifts 
in the expression program [65, 106, 107]. Writers [108] are enzymes which can catalyze 
the addition of PTMs to histones and are divided into families which add specific types 
of modifications. For example, proteins which catalyze the addition of acetyl groups are 
known as histone acetyltransferases (HATs), such as p300/CBP domains, and those 
which catalyze the addition of methyl transferases are known as histone 
methyltransferases (HMTs), such as SET domains. Erasers [108] are enzymes which 
catalyze the removal of modifications from histone tails and are likewise divided into 
families which can eliminate specific modifications from histone amino acids. Families of 
erasers include histone deacetylases (HDACs), such as sirtuins, and histone (lysine) 
demethylases (HDM/KDMs), such as JARIDs and Jumonji domains. Reader domains 
are peptides which have the ability to recognize post-translational modifications of 
histones [109-112]. Although much still remains unknown about readers of several 
modifications, there have been several discoveries and characterizations of histone 
readers in recent years. Examples include bromo domains (recognize acetylated 
histones; first discovered in HATs), chromo domains (recognize methylated histones), 
and Tudor domains (recognize methylation on lysine and arginine residues). 
Repositioning nucleosomes is also critical to maintaining proper chromatin conformation 
dynamics and is largely mediated through chromatin remodeling proteins in an ATP-
dependent manner [113]. Chromatin remodelers (such as INO80, ISWI, or SWI/SNF) 
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are composed of combinations of effector domains (such as for ATPase or helicase 
activity) with one or more reader domains (such as bromo domains to bind histone 
acetylation or HSA domains to bind actin/actin-related proteins) [114, 115]. Through 
recognizing and binding to modified histones, chromatin remodelers are able to use 
their effector domains to reposition, evict, or otherwise affect nucleosome assembly 
and, thus, effectively regulate the replication, transcription and repair of DNA. Overall, 
the chromatin state of the cell is strongly influenced by the combination of 
writers/erasers and ATP-dependent chromatin remodelers.  
While aberrant behavior of epigenome modifying proteins often does ultimately 
involve a genetic perturbation, subsequent shifts in the epigenetic program (and thus 
transcription) of a cell can provide the evolutionary motive force necessary for 
neoplastic growth and to cultivate the epigenetic plasticity required for the many steps of 
the highly inefficient metastatic cascade [116, 117]. Many histone modifying enzymes 
have been associated with cancer [66]. Some of the well-studied histone modifiers 
include the HDM (KDMs), HMT (SUV39Hs, SETs), HDAC (sirtuins), and HAT 
(p300/CBP) families. The aberrant regulation of such proteins has the potential to play a 
role in the development of essentially every known type of cancer, although the specific 
evolutionary contribution to cancer pathogenesis depends largely on the overall 
progression of the tumor [66]. In principle, abnormal histone modifying proteins can 
drive cancer simply through either inactivation of tumor suppressor genes or activation 
of oncogenes.  For example, SIRT6 is a histone deacetylase and is considered to be a 
tumor suppressor due to the protein’s direct interactions with HIF1α and MYC. SIRT6 
typically co-represses HIF1α (hypoxia-inducible factor-1α), a gene which induces 
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glycolytic enzyme expression and a Warburg-like metabolic phenotype [118, 119], and 
MYC, an oncogene involved in ribosome biogenesis, glutaminolysis, and driving cell 
cycle progression [120]. SIRT6 has also been suggested to suppress stem-like 
phenotypes in cancer cells [121]. As one might imagine, in cancer, SIRT6 can suffer 
fatal indels, point mutations, or expression become otherwise lost, thus fueling 
deregulated metabolism and a stem-like state in the cell.  
In eukaryotes, the N-terminal tail of histone subunits extend into the surrounding 
nuclear space and post-translational modifications to these tails contribute to overall 
chromatin conformation and DNA accessibility [122-124]. A small plethora of possible 
PTMs exist and include lysine-specific sumoylation, ribosylation, and ubiquitination, and 
arginine/lysine-specific acetylation and methylation, and serine/threonine-specific 
phosphorylation [125].  Recent research has shown the presence of several new lysine 
acylations, specifically crotonylation, hydroxyisobutyrylation, propionylation, 
malonylation, and succinylation [126, 127]. Many of these new acylation modification 
sites are suggested to overlap known acetylation and are thought to be tied closely to 
metabolic activity within a cell. For example, proprionyl-CoA is produced via oxidation of 
odd-chain lipids and catabolic breakdown of branched-chain amino acid [128] and 
butyryl-CoA is produced as an intermediate metabolite of lipid β-oxidation [126]. As 
described earlier, the overall epigenetic program is closely tied to the activity epigenome 
modifying enzymes, which generally rely on mitochondria-derived metabolic substrates 
and intermediates as metabolites [129]. This most recent research on histone lysine 
acylation further builds support for the concept of linking metabolism and metabolic 
state with chromatin conformation [126].  
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Intriguingly, there exists essentially a cyclic crosstalk between metabolism and 
epigenetics [130].  The level and subsequent catalytic activity of enzymes responsible 
for cellular metabolism directly control production of downstream metabolites such as 
acetyl-CoA, SAM, and NAD+. Epigenome modifying enzymes (such as HATS, HMTs, 
and DNMTs) utilize the metabolic substrates in order to write the epigenetic program of 
a cell. Epigenetic modifications (such as histone PTMs and DNA methylation), in turn, 
can directly control the expression of the metabolic enzymes responsible for producing 
the required substrates in the first place [130]. Apart from a marked shift towards 
Warburg-like glycolysis, metabolic pathways can be disturbed as a result of sustaining 
mutations in proteins involved in the metabolic pathways themselves (such as 
converting an intermediate metabolite into a substrate usable by epignome modifying 
proteins) [131]. Several examples of such mutated metabolic enzymes include isocitrate 
dehydrogenase 1 and 2 (IDH1/2), fumarate hydratase (FH), succinate dehydrogenase 
(SDH), and 5-methylthioadenosine phosphorylase (MTAP). One of the first discoveries 
made (linking epigenetics and metabolism in cancer) was through the observation that 
IDH1/2 can sustain gain-of-function mutations in cancer, which results the generation of 
(R)-2-hydroxygluatrate via reduction of 2-oxoglutarate, an important substrate of the 
Jmjd-type histone demethylases (such as KDM4) and TET 5-methylsytosine 
hydroxylases [132]. The result of mutated IDH1/2 is ultimately histone and DNA 
hypermethylation associated with cancer pathogenesis [133]. In a similar manner, loss-
of-function mutations to FH and SDH result in high levels of fumarate and succinate, 
which is able to inhibit α-kg-dependent histone demethylases (again, such as KDM4) 
and DNA demethylases [134]. The result of FH and SDH loss is a gain of histone and 
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DNA hypermethylation [135]. Furthermore, one study found FH dysfunction and the 
subsequent accumulation of fumarate are able to repress TET DNA demethylase 
activity and induce EMT (thus contributing to cancer progression). Intriguingly, another 
study even suggested that most of the observed variation in DNA methylation programs 
could ultimately be due to differences in expression of proteins involved in one-carbon-
metabolism (SAH-SAM) and methionine SAM salvage [134]. While mutations in 
metabolic enzymes themselves are fairly rare in cancer, the ability to generate aberrant 
epigenetic programs independently of metabolism is a cancer cell’s dream. Epigenetic 
plasticity is a critical evolutionary catalyst which enables cells to overcome challenges 
faced over the course of disease progression. Fortunately, our ever-improving 
knowledge of epigenome-metabolome dynamics has resulted in significant progression 
in efficiently targeting treatments [134]. One study observed that nutrient heterogeneity 
within the interior/microenvironments of melanomas resulted in decreased α-kg levels 
and, accordingly, in increased hypermethylation due to diminished activity of Jmjd-type 
histone demethylases such as KDM4 family members. The result of this 
hypermethylation was resistance in the melanoma to BRAF inhibitors. Once the BRAF 
inhibitors were paired with HMT inhibitors, BRAF resistance was able to be overcome. A 
final interesting therapy indirectly-involving KDM4 family members involves the gain-of-
function mutations in IDH1/2. A small molecule inhibitor (AG-221) of IDH1-/2 mutant 
was able to effectively diminish intracellular concentrations of 2-hydroxyglutarate and, 
thus, reverse the previously observed histone hypermethylation through the action of 
Jmjd-type HDMs, including KDM4 family members [134]. As is clear, there is a strong 
link between metabolism and the epigenetic program within a cell. However, despite 
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recent advances, there is still very much to learn about characterizing the dynamics 
between metabolism and chromatin and epigenetics and how to apply that knowledge 
to best treat disease. 
Developing methods through which to reliably and accurately study mitochondria-
mediated effects in cancer, however, is a challenge. Over the years, several different 
models have been developed in order to study the contribution of mitochondria to 
tumorigenesis. In vitro models include using fibroblast lines, p0 cells or cybrids, while in 
vivo models mostly utilize mice. Patient-derived fibroblasts have been isolated and 
cultured from patients with mitochondrial diseases or mtDNA mutations [136]. 
Unfortunately, while fibroblasts allow for potential therapeutics to be evaluated in vitro, 
the overall consequence of mitochondrial defects in fibroblasts can be difficult to 
ascertain due to metabolic variation (OxPhos vs glycolysis) observed using different 
culture conditions [137]. Further, such fibroblasts are—alone— generally non-
tumorigenic and thus not the best model to use. An alternative to using patient-derived 
fibroblasts is the p0 model for studying the effects of depleted mitochondria, which 
utilizes mammalian cells treated with ethidium bromide in order to perturb the structure 
and function of mitochondria (and thus deplete mtDNA) [138]. Unfortunately, EtBr can 
result in hindered cell proliferation, is genotoxic, and can lead to under desired off-target 
perturbations of the nuclear genome [135]. As with patient-derived fibroblasts, the p0 
model is likewise not an ideal model for studying the role of mtDNA in cancer. Another 
possible method consists of developing a cybrid cell line, wherein a cell with the nuclear 
genome of a cancer line and with the mitochondrial genome of another cell line are 
created. In this situation, the cybrid models can be used to address whether or not 
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certain phenotypes or other traits result from changing the nuclear or mitochondrial 
genomes [139, 140]. This model is more useful as the cybrid cells are indeed 
tumorigenic and can thus reliably be used in vivo [135]. A downside to the model is the 
dependency on mtDNA variants present in patients.  
In regard to animal models available for studying mitochondrial contribution to 
cancer, various different models are in use [135]. Small animal models using zebra fish, 
nematodes, or fruit flies are also viable methods options for studying the effects of 
mitochondria in disease pathology, although such organisms do not, of course, contain 
the same organs as humans [141, 142].  Murine models are very useful for investigating 
the role of mtDNA in cancer as many variables that could not readily be controlled in 
patients can be directly controlled by a researcher using mice as subjects. Three useful 
murine models for studying the relationship between mitochondrial haplotype and 
cancer have been developed, including conplastic mice, mito-mice, and MNX mice. 
Conplastic mice are bred through many backcrosses in order to have the nuclear 
genome from one strain and the mitochondrial haplotype of another strain [143]. Using 
this model, one can observe the contribution of mtDNA to complex diseases, although 
the process of conducting enough backcrosses takes several years and the nuclear 
genome may not be 100% the same as the target strain.  Another in vivo mouse model 
is the mito-mice (transmitochondrial) model, whereby various levels of mitochondrial 
heteroplasmy are assessed for their contribution to disease against a single nuclear 
genome. In the mito-mice model, a mitochondria donor cell with a specific mtDNA 
mutation is selected and the nucleus is removed in order to generate cytoplasts, which 
are fused with a rho-0 cell in order to generate a cybrids [144, 145]. After the genome if 
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the cybrid is removed, the cybrid can either be fused whole with an embryo in the pro-
nuclear stage, or the cybrid can be treated with rhodamine-6G in order to deplete the 
mtDNA, whereupon the cybrid is fused with an embryonic stem cell and subsequently 
injected into an 8-cell mouse embryo before implantation. Due to off-target genotoxic 
effects of mitochondria-depleting compounds, however, the mito-mouse model is not 
optimal for studying the contribution of mtDNA to tumorigenesis and metastasis [135].  
A suitable alternative to the mito-mouse model is the Mitochondrial Nuclear 
Exchange (MNX) mouse model [146]. MNX mice are generated from fertilized oocytes 
with a certain mitochondrial haplotype, which have their nuclear genome removed and, 
in place, are microinjected with the nuclear genome from another mouse strain before 
being implanted into a female mouse. As previously discussed above, in 2006, Kent 
Hunter revealed that the host genetic contribution to metastatic cancer formation may 
be significantly more complex than originally anticipated [26]. In his experiment, Hunter 
bred male FVB/NJ-TgN(MMTV-PyMT)634Mul mice (transgenic mice expressing the 
polyoma middle-T antigen), which present with spontaneous tumors within 60 days 
and roughly 90% of the mice form secondary growth in their lungs within 100 days, with 
female mice of several different inbred stains. The result was that mice formed 
pulmonary metastases to significantly varying degrees. The intuitive explanation for this 
observation would be that the differences are likely due to the nature of the nuclear 
genome and this hypothesis supported due to the discovery of several metastasis 
suppressor genes. Critically, however, what Hunter did not evaluate was the possibility 
that the observed differences in disease could have been due to maternally-inherited 
mitochondrial haplotypes of the mice. 
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Using the unique Mitochondrial-Nuclear Exchange (MNX) mouse model to study 
the effects of varying the type of mitochondria in regard to cancer progression and 
metastasis—in addition to studying the interactions of mitochondria with the DNA 
present in the nucleus of the cell—previous research in the lab of Dr. Danny R. Welch 
showed that mitochondrial haplotype does have a significant influence on the rate of 
both tumor formation and metastasis [147]. Previous experiments in the lab have also 
shown that mice with different mitochondrial backgrounds have distinct patterns of gene 
expression and DNA methylation [148]. As a corollary to these findings, the research 
project for this Master’s thesis was interested in investigating other critical epigenetic 
mechanisms through which mitochondrial haplotype is able to influence which genes 
are turned on or off in the cell. Given the tight link between mitochondrial metabolism 
and epigenetics, the logical hypothesis was simply that the mitochondrial haplotype is 
likewise able to influence the epigenetic process of post-translationally modifying the N-
terminal tails of histones (in order to affect chromatin state dynamics in the cell. Thus, 
this thesis project sought to observe whether or not histone modification profiles are 
different depending on the mitochondrial haplotype present of each strain of MNX 
mouse examined. The results of this research will not only contribute to our 
understanding of how mitochondria participate in influencing the DNA packaging 
mechanisms involved in turning genes on or off, but, as our research is not limited to 









For the ChIP-Seq experiment, cerebella from four different strains of mouse (mus 
musculus) were harvested, snap frozen in liquid nitrogen and stored at -80°C until use.  
Specific strains included: C57BL/6Jwt,  C3H/HeNwt,  C57BL/6J(n):C3H/HeJ(mt), and 
C3H/HeJ(n): C57BL/6J(mt). All brain samples originated from 8 week old, male mice.  
 
 
Histone Acid Extraction 
 
Cells at ~75% confluence were harvested and washed twice with ice-cold PBS (or one 
could use roughly 25 mg of tissue). Cells or Dounce-homogenized tissue samples were 
suspended in Triton Extraction Buffer (TEB: PBS containing 0.5% Triton X 100 (v/v), 2 
mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3) at a cell density of 107 
cells per mL Cells were lysed on ice for 10 min with gentle stirring and then centrifuged 
at 6,500 x g for 10 min at 4°C to spin down nuclei. Supernatant was removed and 
discarded. Nuclei were washed in half the volume of TEB and centrifuged as before. 
Pellet was resuspended in 0.2 N HCl at a density of 4x107 nuclei per mL. Histones were 
acid extracted over night at 4°C. Samples then centrifuged at 6,500 x g for 10 min at 
4°C to pellet any debris. Supernatant was then saved, which contained the histone-
enriched fraction, and protein content then determined using BCA assay. Aliquots 





Western Blot Analysis 
 
For whole cell lysate, cells were washed in 5mL PBS twice, whereafter 300 µL of RIPA 
with 1% (3 µL) HALT 100X protease inhibitor cocktail (EDTA-free) was added to the 
plate and incubated on ice for 15 minutes. Cells were scraped and transferred to 
microcentrifuge tubes, which were then centrifuged (15 min, 13,000 RPM, 4°C). After 
spinning, supernatant was transferred into fresh microcentrifuge tube and stored at  
-80°C. 
 
For cytoplasmic and nuclear protein fraction isolation, a NE-PER Nuclear and 
Cytoplasmic Extraction Kit protocol was followed. CER I, CER II, and NER I solutions 
were supplemented with 1% HALT (EDTA-free).  
 
To quantify the concentration of the protein fractions, a Pierce BCA (Bicinchoninic Acid) 
Protein Assay Kit was used. No deviations from the standard protocol (microplate 
procedure) were made. After 30 minutes incubation, absorbance was read at 562nm 
and the protein concentrations were thus determined.  
 
Bis-Tris SDS gels were made in lab according to the following protocol:  
 
4% stacking gel: 6.8 mL dH2O, 1.25 mL Tris pH 6.8, 1.7 mL 30% bis-acrylamide, 100 µL 10% 
SDS 
To initiate polymerization, add 100 µL 10% ammonium persulfate (APS) and 10 µL 
TEMED (to 10 mL gel solution) 
 
12% resolving gel: 3.3 mL dH2O, 2.50 mL Tris pH 8.8, 4.0 mL 30% bis-acrylamide, and 100 µL 
10% SDS 
To initiate polymerization, add 100 µL 10% ammonium persulfate (APS) and 4 µL 




Prior to casting Bis-Tris SDS gel, protein samples of each fraction (20-50 µg; 
WCL/Cyto/Nuc) were diluted with 4X Lithium Dodecyl Sulfate (LDS) sample buffer 
supplemented with ß-Mercaptoethanol (10% v/v) and heated to 95°C (> 5 min), before 
being brought back to room temperature.  
 
Once fully polymerized, the gel was placed in an appropriately sized electrophoresis 
chamber with/without a buffer dam. The well comb was removed carefully from gel and 
the chamber then filled with desired running buffer (1X Tris/Glycine/SDS; 1X MES SDS; 
1X MOPS; etc). Samples were transferred to individual wells, in addition to desired 
protein ladder /marker. The gel was run at 100V until dye front reached bottom of gel. 
 
After completion of electrophoresis, the gel was transferred to a PVDF/nitrocellulose 
membrane using either a commercial transfer pack (Bio-Rad Turbo) or a homemade 
transfer stack.  For the homemade transfer stack using PVDF, 1X transfer buffer (with 
10% v/v methanol) of the desired composition was made. Two extra-thick transfer pads 
were equilibrated in the activated transfer buffer. The PVDF membrane was activated 
by soaking in 100% methanol for ~5 sec and then moved to 1X activated transfer buffer 
and soaked. Once ready, PVDF membrane was placed on one of the thick transfer 
pads in the transfer tray; the membrane was pre-cut with an orientation mark (removed 
top left corner, etc). The gel was then carefully removed from its cassette and placed 
atop the PVDF, paying close attention to sample order orientation. A roller removed air 
bubbles between the gel and the membrane. The second thick transfer pad was placed 
atop the gel and again the roller was used to remove air bubbles. The transfer tray was 
29 
 
locked, placed in the transfer unit, and the desired transfer protocol (high/low MW, 
standard, etc) selected. After complete transfer, the PVDF membrane was removed and 
placed immediately in TBST+5% skim milk. Membrane was blocked for at least one 
hour at RT, or overnight at 4°C.  
 
Once the membrane had blocked, primary antibody was added and incubated at room 
temperature for one hour or overnight at 4°C. After incubating, antibodies were removed 
and the membrane was washed three times for 5 minutes each in TBST. Secondary 
antibody was added and incubated again at room temperature for one hour or overnight 
at 4°C. After incubating, secondary antibodies were removed and the membrane was 
washed three times for 5 minutes each in TBST.  
 
The membrane was imaged using Thermo Fisher West Dura or Femto (high sensitivity) 
Kit. Imaging reagent solutions were mixed at 1:1 ratio, added to the membrane, and 
incubated for 5-8 minutes in a dark place (or cover the membrane case with foil). 
 
To strip PVDF after imaging, the membrane was washed three times with TBST and 
soak membrane in Thermo Scientific Restore PLUS stripping buffer for 5 to 15 minutes 
at room temperature. Stripping buffer was removed and the membrane washed with 
TBST. The membrane was re-blocked for 1 hour at RT as previously described. 





Modified Histone Peptide Array 
 
To validate antibody specificity prior to ChIP-Seq, an EMD Millipore AbSurance H3 
Peptide Array (#16-667) was used. Manufacturer instructions were followed. Primary 
antibody dilutions ranged from 1:8,000 to 1:10,000. Secondary antibodies were diluted 





anti-H3K4me1 – Abcam – ab8895, polyclonal rabbit IgG (lot: GR3186715-1) 
anti-H3K4me3 – Abcam – ab8580, polyclonal rabbit IgG (lot: GR3190162-1) 
anti-H3K27ac – Abcam – ab4729, polyclonal rabbit IgG (lot: GR3187599-1) 
anti-H327me3 – Cell Signaling – 9733, monoclonal rabbit IgG 







Flash-frozen, mouse brains (cerebella) were weighed and transferred to a mortar and 
pestle pre-chilled in liquid nitrogen. Brain tissue was pulverized to a fine, homogenous 
powder and subsequently added to 1% formaldehyde/1X PBS solution for protein 
crosslinking. After 10 minutes of fixing at room temperature, the samples were spun 
briefly and the supernatant discarded. Tissue was resuspended in 1 M Tris 8.0 pH and 
placed on a rocker for 10 minutes at room temperature to quench the crosslinking 






Samples were resuspended in ice-cold B1 hypotonic lysis buffer supplemented with 
HALT 100X EDTA-free protease inhibitor cocktail (PIC) and transferred to a 7 mL 
Dounce homogenizer with “tight” pestle for mechanical disruption of the outer plasma 
membrane. Samples were dounced between 50-60 strokes to ensure thorough 
membrane disruption. After douncing, sample was sieved through a 100 µm nylon 
DNase/RNase-free cell strainer into a new 50mL conical tube and centrifuged at 800g, 
4°C, for 5 minutes. Supernatant (cytoplasmic fraction) was discarded and the nuclei 
resuspended in ice-cold S1supplemented with PIC. The resuspended S1 solution was 
transferred on top of the ice-cold S2 solution (with PIC) to create a sucrose gradient. 
The sucrose solutions were spun at 3000RPM, 4°C. for 10 minutes. The supernatant 
was carefully removed with a 10 mL pipette and discarded. The isolated nuclei pellet 
was resuspended in sonication/lysis buffer supplemented with PIC and allowed to 
incubate on ice for at least 10 minutes to ensure lysis of nuclear membranes.   
 
For sonicating chromatin, samples were aliquoted to 0.6 mL tubes (200 µL/tube) to 
ensure even and consistent shearing. Using an ActiveMotif temperature-controlled 
water bath (indirect) sonicator, chromatin samples were sheared for 27 minutes total, 
using a cycle of 10 sec ON, 5 sec OFF, and 75% amplitude. The sonicator was briefly 
turned off every 5-7 minutes to allow the water bath to return to 2°C in order to ensure 
the samples did not overheat. After sonication, sample aliquots were returned to 1.7mL 




To validate shearing of samples (fragment bands between 100-600bp), an agarose 
DNA gel was run. 25 µL of sheared chromatin was transferred to a 1.7 mL 
microcentrifuge tube, along with 250 µL elution buffer (supplemented with 250 mM 
NaCl). Crosslinks were reversed by incubating at 85°C for 2 hours. After reversal of 
crosslinks, 1-2 µL RNase/T1 were added to each sample and incubated for 30-60 
minutes at 37°C. After RNase digestion, 1-1.5 µL Proteinase K was added to each 
sample and incubated to 30-60 minutes at 48°C. 500 µL phenol-chloroform was then 
added to the samples, vortexed briefly, and centrifuged at max speed, 4°C, for 20 
minutes. The top layer was transferred to a new tube containing 900 µL 100% EtOH 
and glycogen (1000 µL:1 µL ratio). DNA was precipitated from 1hr to overnight before 
being centrifuged at max speed, 4°C, for 20 minutes. After spinning, the supernatant 
was discarded and 500 µL 80% EtOH added. Samples were vortexed briefly to 
resuspend the pellet and centrifuged at max speed, 4°C, for 20 minutes. After spinning, 
the supernatant was discarded and DNA pellet allowed to air dry for 15-20 minutes.  
DNA was resuspended in 20-30 µL H2O and mixed with 6X loading dye. Samples and 1 
kb marker ladders were loaded on a 1.5% agarose gel in 1X TAE and run at 100V until 
sufficiently resolved.  
 
Once proper fragmentation of chromatin (100-500bp, minimal higher molecular weight 
bands) had been assured, protein concentrations were estimated using a Pierce BCA 
(bicinchoninic acid) Protein Assay Kit was used. No deviations from the standard 
protocol (microplate procedure) were made. After 30 minutes incubation, the 
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absorbance was read at 562 nm on a plate reader and the protein concentration thus 
determined.  
 
After determination of protein concentrations, Dynabeads were prepared. Dynabeads 
(Protein A) were resuspended in their vial (vortexed briefly) and an appropriate volume 
of Dynabeads added to 1.7 mL low-bind microcentrifuge tubes. The volume of beads 
was adjusted based on required binding capacity (i.e., amount of antibody required).  
Bead tubes were placed on magnetic rack to separate beads from the stock solution 
and supernatant was discarded. Beads were washed with 200-400 µL 1X PBS+0.1% 
Tween-20. To pre-bind desired antibody to the beads, antibody was diluted in 100 µL 
1X PBS+0.1% Tween-20 to the Dynabeads. The antibodies and beads were incubated 
with rotation 2 hours at room temperature. After pre-binding, tubes were placed on 
magnetic rack and supernatant discarded. The antibody-bead complexes were gently 
washed in 400-800 µL 1X PBS+0.1% Tween-20. 
 
To set up the immunoprecipitation reactions, 15-75 µg sonicated chromatin was added 
per test sample tube and matching IgG tube (equal volume of antibody). Bead-
chromatin samples were diluted at least 1:10 using IP buffer and incubated overnight 
with rotation. IP volumes ranged from 100 µL to 500 µL (depending on antibody used). 
Inputs for each individual mouse were generated by transferring 470 µL elution buffer to 
1.7 mL low-bind microcentrifuge tubes and adding 20 µL sonicated chromatin to the 
tubes (one input per unique individual/mouse).  After completion of IP incubation, 
samples were washed six times to reduce background binding. First wash: 1000 µL 
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wash buffer #1 for 5 minutes with rotation at 4°C. Second wash: 1000 µL wash buffer #2 
for 5 minutes with rotation at 4°C. Third wash: 1000 µL wash buffer #3 for 5 minutes 
with rotation at 4°C. Fourth wash: 1000 µL of wash buffer #4* for 5 minutes with rotation 
at 4°C (*made fresh 1X wash buffer #4 with 1% sodium deoxycholate + H2O).  Fifth and 
Sixth washes: 1000 µL TE for 3 minutes with rotation at 4°C. Each sample was eluted in 
500 µL ChIP elution buffer at 65°C for >= 30 minutes with occasional vortexing/hand-
turning. After incubation, non-input samples were transferred to clean 1.7mL low-bind 
microcentrifuge tubes. To reverse crosslinks, both input and non-input sample tubes 
were supplement with 20 µL 5M NaCl and incubated for at least 15 hours at 65°C. 
RNAse A/T1 was then added to each sample and incubated at 37°C for two hours. To 
digest remaining proteins, 1-1.5 µL Proteinase K was added to each tube and incubated 
at 48°C for three hours. Lastly, DNA was purified using a column-based QIAquick PCR 
Purification Kit (eluted in 35 µL molecular biology-grade H2O) and quantified using a 





Libraries for sequencing were generated according to the Illumina TruSeq ChIP-Seq 
Sample Prep Protocol, available from the Illumina website  








ENCODE guidelines and recommendations for sequencing were followed.  ChIP DNA 
samples and input were sequenced using an Illumina HiSeq2500 TruSeq.v3 High 
Output platform (100bp single reads). “Broad” histone modifications (H3K4me1 and 
H3K27me3) were sequenced to a target of 45 million mappable reads. “Narrow” histone 
modification (H3K4me3 and H3K27Ac) were sequenced to a target of 20 million 
mappable reads. Inputs for each individual sample were sequenced to a target of 60 
























Figure 1  Experimental Outline. For this ChIP-Seq experiment, four lines of 
Mitochondrial Nuclear Exchange (MNX) mice were used, including two isogeneic, 
biological replicates per strain. Cerebellum samples were harvested from eight week old 
male mice and flash frozen with liquid nitrogen. Brains were initially homogenized via 
cryopulverization and then fixed for 10 minutes in 1% formaldehyde. After quenching 
the fixation reaction, brain homogenate was dounced 50-60 times, run through a 100 
µm filter, and the nuclei isolated using a sucrose gradient. After adding lysis buffer, 
nuclei were sonicated for 27 minutes total (10 sec ON, 5 sec OFF, 75% amplitude) in a 
temperature-controlled water bath. Sonicated chromatin fragmentation was visualized 
on an agarose gel and the protein content quantified via BCA assay. For setting up the 
immunoprecipitation reaction, antibodies were pre-bound with Dynabeads for two hours 
before starting the IP. With an appropriate amount of chromatin, IPs ran for 15 hours 
before being washed and eluted. Post-ChIP DNA was purified using a QIAquick PCR 
purification kit. Upon submission to the sequencing core, DNA was run on an Agilent 
Bioanalyzer to further verify chromatin fragment length. After index/sample libraries 
were built, sequencing was conducted on an Illumina HiSeq2500. Broad histone 
modifications (H3K4me1/H3K27me3) were sequenced to a target of 45 million reads, 
whereas narrow histone modifications (H3K4me3/H3K27ac) were sequenced to a target 
of 20 million reads. Post-sequencing analysis was conducted in collaboration with Dr. 
Devin Koestler and Dr. Dong Pei in the KUMC Biostatistics department. Tools used to 
analyze sequencing data include FastQC, IGV, DiffBind, PAVIS, and Gene Ontology. 
Mouse strain key: CC = C57BL/6Jwt, CH = C57nuclear, C3H mtDNA, HC = C3Hnuclear, C57 





Primary Antibody Validation 
 
Before beginning the ChIP-Seq experiment itself, evaluating both the specificity 
and the selectivity of the chosen antibodies was necessary. Following published 
ENCODE project guidelines for primary and secondary antibody validation 
methodology, the first means of antibody evaluation consisted of immunoblotting using 
histone-enriched fractions obtained through acid extraction of B16F10 mouse 
melanoma whole cell lysate. For the immunoblots, concentration gradients of histone-
enriched fractions were used in order to evaluate optimal, specific signal response and 
to monitor for potential off-binding events at different protein concentrations. As can be 
observed in the blots of figure 2, there are clear signals at 17 kDa for each antibody 
evaluated. No other bands are readily visible, except for some faint events around 75 
kDa at higher loading concentrations for H3K4me1. For H3K27me3, there appear to be 
very faint background bands at roughly 50 kDa, though there is also background 





















Figure 2  Primary antibody validation (immunobloting). Concentration 
gradients of histone-enriched fractions were used in order to evaluate optimal, specific 
signal response and to monitor for potential off-binding events at different protein 
concentrations. All antibodies were diluted 1:1000 (primary), 1:5000 (secondary). 









Secondary Antibody Validation  
 
Following primary evaluation of the candidate antibodies using immunoblots, the 
antibodies were further tested using an ENCODE-recommended secondary 
characterization method. In order to determine the selectivity of the antibodies, a 
commercial peptide array from EMD-Millipore was used. The peptide array features 48 
different recombinant post-translationally modified histone epitopes at two different blot 
concentrations. Four species-specific isotype controls (rat, sheep, mouse, rabbit) are 
also included. As seen in figure 3, all antibodies displayed very strong binding at a 
primary target and signals from the rabbit IgG controls were visible. Off-target events 



















Figure 3    Secondary antibody validation (peptide array). Commercial peptide 
arrays were obtained from EMD-Millipore. The peptide array features 48 different 
recombinant post-translationally modified histone epitopes at two different blot 
concentrations. Four species-specific isotype controls (rat, sheep, mouse, rabbit) are 
also included. Primary antibody dilutions were as follows: H3K4me1 (1:9000), H3K4me3 
(1:9000), H3K27me3 (1:10000), H3K27ac (1:8000). All secondary antibodies were 






After successful completion of antibody characterization, the ChIP-Seq 
experiment itself was begun. A minimum of 20 ng of post-ChIP DNA was collected for 
each antibody per mouse and submitted to the sequencing core facility at KUMC. Upon 
receipt of sequencing data, all fastq files were initially evaluated for overall quality using 
the FastQC program. In figure 4, one representative sample was chosen. As is visible, 
the average percentage of duplicate reads ranged anywhere from around 10% up to 
roughly 20%.  The mean quality score (i.e., the Phred score) for reads generally 
remained around 30. Interestingly, one consistent drop in read quality was visible in one 
specific input subgroup in many specimens (as seen by the drop in the average read 
quality Phred score to below 30 at roughly 80 bp). Furthermore, when observing the 
quality per tile in the flow cell, a large stretch of red and warm color (low Phred score) 
reads is visible. In order to correct this dip in quality, the specific input files containing 
the errors were trimmed to include only the reads prior to the 70 bp read length. As is 
visible, the read quality chart no longer features a decrease in read quality following 




















Figure 4  Post-sequencing read quality evaluation using FastQC. A) General 
statistics for read subgroups, including the percentage of duplicate reads, percent GC 
content, and number of reads per subgroup. B) Representative mean quality scores 
(Phred scores) for the experiment.  Higher Phred scores indicate less probability of 
erroneous base calls being made.   C) Overall quality per tile is a visual representation 
of the read locations within the sequencing flow cell. Solid blue indicates high Phred 
scores, whereas warm colors indicate lower Phred scores and lower read quality.  D) 
(left) Pre-trimming quality scores across all bases. (right) Post-trimming quality scores 
across all bases. Higher Phred scores (green region of chart) indicate less probability of 













As all data sets passed initial quality control checks (or were otherwise 
corrected), sequence data were used to generate a series of volcano plots in order to 
investigate the fold changes and relative P values of ChIP signal when comparing two 
mouse strains. Given the lab is concerned with addressing the extent to which 
mitochondrial background influences the histone modification profiles, three main 
comparisons were utilized: CC vs. HH, CC vs. CH, and HC vs HH. Intriguingly, in 
reference to figure 5, while several “hits” were below the P value significance of 0.05, 
very few data points (only in H3K4me3 sets) were above the adjusted significance value 
as determined using the Bonferroni correction. Gene names in red indicate matches 
with previously identified RNA-Seq genes (does not indicate significance), whereas 
black genes have not been matched to previous RNA-Seq gene lists. For the H3K4me1, 
H3K4me3, and H3K27me3 shifts in the “hit” profiles between different strain 

















Figure 5  Volcano plots of post-differential binding analysis. A) Differential 
H3K4me1 (enhancer/gene body mark; active transcription) loci.  B) Differential 
H3K4me3 (promoter region mark; active transcription) loci.  C) Differential H3K27me3 
(repressed transcription). D) Differential H3K27ac loci (enhancer/gene body mark; 
active transcription). Black bar indicates a P-value threshold of 0.05. Blue bar indicates 
an adjusted P-value via Bonferroni correction. Red circles indicate hits above the 
adjusted threshold. Red gene names indicate direct matches with previous RNA-Seq 















Lastly, in order to visually verify changes in histone modification profiles between 
strains, IGV (Integrative Genomics Viewer) was used. Data tracks were loaded into IGV 
(including input tracks) and, initially, well-known active or suppressed gene loci were 
viewed. As can be seen in figure 6, H3K4me1, H3K4me3, and H3K27ac marks were 
present within the GAPDH gene. Specifically, H3K4me1 can be seen to localize 
upstream of the TSS (in addition to within the gene itself), H3K4me3 is generally located 
close to the TSS and initial exons, and H3K27ac closely matches the pattern exhibited 
by H3K4me3. Importantly, H3K27me3 is completely absent at this locus. Upon viewing 
a well-known repressed gene, such as EVX1, the only strong signal is H3K27me3. After 
determining that the observed signal patterns at control loci closely matched those of 
published ENCODE ChIP-Seq data sets, other loci were examined to determine 
whether or not the reported signals mapped back to known genes. One of the hits from 
the RNA-Seq data set (Glo1) was reported to have a differential H3K4me1 profile in the 
ChIP-Seq dataset as well. As can be seen in figure 5, when comparing CC140 and 
CC142 with HC351 and HC376, there is more H3K4me1 signal throughout the Glo1 























Figure 6  Visualization of ChIP-Seq data using IGV (integrative genomic 
viewer). A) Verification of peak pattern at a well-known, actively-expressed control 
(GAPDH). Two replicate mice of one strain (HC) shown. All four antibodies loaded into 
tracks.  H3K4me1 (orange); H3K4me3 (green), H3K27me3 (red), H3K27ac (blue), Input 
tracks for each strain (black).  B) Verification of peak pattern at a well-known, repressed 
control (Evx1). Two replicate mice of one strain (HC) shown. All four antibodies loaded 
into tracks.  H3K4me1 (orange); H3K4me3 (green), H3K27me3 (red), H3K27ac (blue), 
Input tracks for each strain (black).  C) Verification of differential binding results at the 
Glo1 locus. Two replicates from each strain CC and HH shown. Only one antibody 



























Figure 7  Top gene hits from annotation of differential binding analysis data. 
For each antibody, the top five genes (based on absolute log fold-change) were 
determined for three sets comparisons. logFC = log fold-change (base 2), absolute log 
fold-change, FDR = false discovery rate, distance to TSS = distance to transcription 
start site. Data annotated using mm10 and PAVIS. For H3K4me1, nearest gene was 
defined by 5 kb upstream and 1 kb downstream. For H3K4me1, nearest gene was 
defined by 5 kb upstream and 1 kb downstream. For H3K4me3, H3K27me3, and 

















Overall, the objectives of the experiment were able to be successfully met. After 
conducting ChIP-Seq using brain tissue (cerebellum) from different strains of MNX 
mice, clear differences in histone modification profiles were observed, thus suggesting 
that mitochondrial haplotype does play a significant role in contributing to the dynamics 
of histone PTMs.  
From the outset, significant emphasis was placed on quality and reproducibility. 
As recent publications have shown that a sizable proportion of commercial antibodies 
do not perform as promised, all antibodies used for ChIP-Seq were subject to initial 
characterization and validation. For histone modification antibody validation, ENCODE 
project guidelines were closely followed. Upon selection of the antibodies to be used, 
immunoblot assays using histone-enriched fraction from acid-extracted B16F10 whole 
cell lysate were run. The results were very encouraging. For all four antibodies tested 
(H3K4me1, H3K4me3, H3K27me3, and H3K27ac), almost no non-specific bands were 
observed. Though banding was present at around 50 kDa (whereas the expected 
molecular weight of histone H3 is around 17 kDa), the bands were very faint and well 
within ENCODE’s suggested criteria of the target band exhibiting (at least) ten-fold 
signal strength compared to any off-target bands. In addition, the histone-specific band 
should comprise at least 50% of the total protein signal. As can be readily seen in figure 
2, all four antibodies passed this initial characterization step.  
Once candidate antibodies were shown to be sufficiently specific via immunoblot 
analysis, secondary characterization of the antibodies was conducted using a 
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commercial (EMD-Millipore) peptide array. On this array, 46 common post-
translationally modified recombinant histone peptides (at two dot concentrations of 10 
and 100 ng) were present, in addition to species-specific IgG positive controls. As 
depicted in figure 3, all four antibodies exhibited strong binding at the anticipated 
recombinant histone peptide loci. Unfortunately, determining the optimum concentration 
for the peptide array proved difficult. Mild chemically-similar off-target binding events 
were visible for H3K4me1, H3K4me3, and H3K27ac. For H3K4me1 and H3K4me3, the 
signal strength was so strong (even at low dilutions) that the positive control could only 
be imaged when the signal from the recombinant peptides was concealed with 
aluminum foil and the blot reimaged. As such, one can conclude that the off-target 
events at H3K4me2 for these two antibodies was likely a result of too-high primary 
concentration. Similarly, H3K27ac exhibited mild off-binding at H3K9ac. Thankfully, all 
of the off-target binding events observed have the same association with transcription 
status (active transcription) and, thus, would be unlikely to significantly throw off 
interpretation of ChIP-Seq results downstream. Furthermore, the primary signals are 
easily 10-fold stronger compared to the weaker off-binding targets and falls well within 
ENCODE quality control parameters.  
Upon successful primary and secondary validation of the antibodies, ChIP-Seq 
experiments were conducted and enough DNA for sequencing was collected. Although 
a minimum of 10 ng per sample was necessary as a bare minimum for sequencing, 
actual amount of collected ChIP DNA was 20-30 ng (to hedge against the possibility of 
a failed sequence run and/or inaccurate/low DNA quantitation). After submitting the 
ChIP DNA to the KUMC sequencing core facility and receiving the fastq data files, initial 
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quality control using the FastQC program was conducted. Overall the quality 
parameters looked great for most samples—most samples exhibited low percentages of 
duplicate reads and high Phred scores (low probability of an inaccurately called base). 
One set of samples exhibited fairly high duplicate reads (CH374) for the H3K4me1 
antibody and thus the CH strain H3K4me1 comparisons were dropped. Furthermore, 
stochastic errors during the sequencing run itself were observed. As visible in figure 4, 
one out of seventeen total read batches per sample experienced a sudden drop in 
Phred score, which was reflected as red and warm-color streaks on the flow cell quality 
per tile chart. At roughly 80bp in read length, reads in this tile region displayed sudden 
high probabilities of inaccurate read calls before self-correcting and returning to the 
baseline level of read quality for the end of the read. To address this, the batch of 
affected reads (one out of seventeen) were truncated at the 70bp position and retained 
in the dataset. Upon re-evaluation of read quality with FastQC, the post-correction 
average read quality returned to levels comparable with other read batches. Following 
successful quality control measures, all samples passed visual read quality inspection.  
As a next step, the sequencing data were used to generate a series of volcano 
plots in order to examine whether or not the mitochondrial haplotype of the MNX mice 
had any effects on the overall histone modification profiles observed. Since the lab is 
interested in the mitochondrial-induced shifts, the three main comparisons between CC-
HH, CC-CH, and HH-HC were utilized. In figure 5, clear shifts in the patterns of 
H3K4me1, H3K4me3, H3K27me3, and H3K27ac were all able to be seen. 
Unfortunately, as the fold changes are log scale, the more subtle shifts are likely hidden 
due to most genes densely clustering within the sub-logFC 2 range. Indeed, when using 
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the Bonferroni correction to adjust the P value in order to minimize the likelihood of 
selecting false-positive hits (type I errors) when evaluating multiple pair-wise tests on a 
single dataset, very few statistically significant hits were registered. Only hits for 
H3K4me3 were above the corrected P value threshold.  
Lastly, in order to visually verify that the ChIP-Seq data compared to control loci 
of published ENCODE datasets and in order to visually determine whether or not the 
shifts reported by the  differential binding analysis are genuine, bigwig files for samples 
were loaded into IGV and first examined at genetic loci known to be either strongly 
transcribed or strongly repressed. Visible in figure 6, samples were initially compared to 
the GAPDH locus, which is known to be an actively-expressed housekeeping gene. 
Within GAPDH, H3K4me1 was observed in expected regions (throughout the gene 
body and within enhancer regions), H3K4me3 was localized close to the TSS and initial 
exons, and H3K27ac followed a pattern closely matching that of H3K4me3. Importantly, 
H3K27me3 signal is absent at this locus (as would be expected, given that H3K27me3 
is associated with repressed transcription and heterochromatin). Upon viewing the 
EVX1 locus, however, H3K27me3 signal became very evident and the active 
transcription histone modifications all dramatically decreased. Thus, given that the 
antibody profiles for the control loci were as had been anticipated, chromosome loci 
stemming from the DiffBind analysis were visualized. One good example of differential 
signal strength can be seen in the H3K4me1 signal throughout the Glo1 locus when 
comparing CC and HC. Clearly, there is significantly stronger signal of H3K4me1 
binding in HC (blue) compared to the CC signal (orange). In the RNA-Seq dataset, Glo1 
was upregulated 1.98-fold in HC relative to CC.  Figure 7 provides a brief overview of 
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the top hits between each strain comparison. Functions of the various genes range 
between DNA methylation (Trmt10c), ROS regulation (Nrros), calmodulin-binding 
transcription activation (Camta1), ATP generation (Atp5d), mitochondrial DNA 
replication/repair (polg), and histone lysine methylation (Setdb1). At first glance, many 
of the genes that exhibit differential histone modification profiles are either directly or 
indirectly tied to metabolism. Upon conducting preliminary pathway analysis (not shown) 
using all or directional fold-change DiffBind calls within comparisons, processes as 
diverse as transcript splicing, G-coupled protein receptor and kinase signaling, ATP 
synthesis, and, reassuringly, chromatin remodeling/histone post-translational 
modification have been implicated.  
As should now be clear, high-quality data was able to be generated using the 
given antibodies, validation procedures, and ChIP-Seq protocol. Most importantly, the 
question of whether or not mitochondrial haplotype plays a role in determining the 
relative histone modification profiles between different MNX mouse strains was 
affirmatively answered. Given this new information, several new questions emerge: 
what specifically about the mitochondria is responsible for these changes? Of the genes 
that were differentially identified, which biological pathways could be responsible for 
these changes? How do changes in histone modification profile relate to tumor latency 
and metastasis? Likely candidates for future investigation would be to determine precise 
changes in overall metabolite levels between the MNX mice (which is already underway 
in the lab), conducting integrative epigenomic analysis between the RNA-, Methyl-, and 
ChIP-Seq data sets, or investigating whether or not histone and/or chromatin modifying 
enzymes could be playing a role in generating these differences. Indeed, previous RNA-
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Seq data showed distinct differences in histone acetyltransferase, histone deacetylase, 
and histone demethylase expression. Either of these factors or the combination of the 
two could likely be responsible for the observed differences. Another interesting path for 
future investigation would be to broaden both the total number of histone modifications 
examined via ChIP-Seq and to even investigate the role of more recently characterized 
acyl histone modifications and their link to overall metabolism within an organism. While 
significant, exciting in-roads have been made in regards to the contribution of 
mitochondrial haplotype to both cancer progression and metastasis, many questions still 
remain unanswered. Future research will not only further contribute to our 
understanding of how mitochondria participate in influencing the cellular epigenetic 
mechanisms involved in fine-tuning gene expression, but has the potential to benefit to 
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